news aktuell GmbH

Semdor Pharma Group: Semdor Pharma adds Global Pharmaceutical Executive Rolf Hoffmann to its Board of Directors


30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert.

(Cologne, Germany): Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned global pharma executive and advisor, to its Board of Directors, as well as an investor in the company. Mr. Hoffmann previously served at Amgen as Senior Vice President of Commercial Operations (US) and SVP of International and Europe, where he focused on operations, scaling and organizational development. Mr. Hoffmann started his pharmaceutical career at Eli Lilly as a sales representative, progressing quickly to senior positions including President of Latin America Operations and General Manager in Germany. Since parting from Amgen in 2016, Mr. Hoffmann has served on numerous boards related to the pharmaceutical and biotechnical sector, including STADA (Germany's largest independent Generics/OTC enterprise), Danish Genmab (Europe's largest Biotech company) and EUSA Pharma (a European specialty pharmaceutical company focused on oncology and oncology supportive care), among others.

Semdor Pharma attracted me because of their clear mission of building a next-generation European specialty pharmaceutical company focused on the massive problem of physical and mental pain and suffering. No other condition takes such a large emotional and financial toll on European society and Semdor’s reason for being is clear. No other European platform is able to offer the market such a broad array of life-enhancing medicines, from traditional pain medications to the exploding area of medical cannabis products. Semdor has a generational opportunity and I am excited to impart my experience scaling pharma businesses as a Board Director and investor”, said Rolf Hoffmann.

I am proud of the hard work of every member of the Semdor team and our mission remains clear: offering European patients the most innovative, highest quality pain medicine and related products, whether traditional pain therapies or medical cannabis. We are in a stronger position than ever to build Semdor’s platform, including the Cannamedical brand, as a leader in the European medical cannabis industry” said David Henn, CEO of Semdor “With over 30 year of experience helping develop pharma platforms in Europe, North America and Latin America, , Rolf is a perfect fit as an investor and Board Director.”

About Semdor Pharma Group

The formation of Semdor Pharma Group in January 2021 established one of Europe's leading pharmaceutical groups specialized in narcotics and medical cannabis. Semdor Pharma Group was formed through the merger of the German narcotics services market leader PS Group (including subsidiaries PS Pharma Services, PB Pharma and PS Marketing & Outsourcing) and Cannamedical Pharma, which is the leading independent medical cannabis brand in Germany. Semdor offers European wholesalers, suppliers and pharmacies the broadest array of narcotic medicines (both synthetic and natural) and provides key narcotic and medical cannabis players the broadest selection of market-leading product importing, handling, packaging and formulation services. Semdor Phamra generates gross annual sales of more than 60 million euros and employs 180 team members in Cologne and Meerbusch, Germany.


Leonie Weskott
Phone: +49 (0) 221 9999 6151

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

ARD Presse: CIVIS MEDIA PRIZE 2021 - 23 productions nominated, 5 podcasts for the public vote15.4.2021 11:22:26 CEST | Press release

(Cologne, Germany): CIVIS Media Prize 2021 – The 23 nominees of what is Europe's most important media prize when it comes to integration and cultural diversity have been selected: Candidates for the CIVIS Media Prize include entries from ARTE, Bayerischer Rundfunk, Filmakademie Baden-Württemberg, FYEO, HBO, Mitteldeutscher Rundfunk, Norddeutscher Rundfunk, Österreichischer Rundfunk, ProSieben, Radio Bremen, Saarländischer Rundfunk, Schweizer Radio und Fernsehen, Südwestrundfunk, Westdeutscher Rundfunk and ZDF. The productions deal with highly topical issues such as flight, racism, right-wing extremism and antisemitism in many different ways; however, they also cover strategies against hate and violence as well as strategies for the peaceful coexistence of people with diverse geographical and cultural origins. Nearly 800 productions from television, radio and the Internet were submitted for the CIVIS Competition 2021. They came from 20 EU states and Switzerland. The complete list of nom

Grünenthal Group: Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee12.4.2021 11:47:13 CEST | Press release

With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. (Aachen, Germany) –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and function

Fluxergy, Inc. Receives CE-IVD Marking for a One-Hour COVID-19 RT-PCR Test and Positions for European Market Entry12.4.2021 09:00:00 CEST | Press release

IRVINE, CA., April 12, 2021 – Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy’s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval. Fluxergy’s platform is an automated, sample-to-answer testing platform with multimodal capability allowing for a variety of assay types, such as molecular, immunochemistry, chemistry, and cytometry assays, to be run simultaneously on the same cartridge. This will give users the ability to run unique Point-of-Care (PoC) panels with the potential ability to do built-in reflex testing, among other capabilities. Potential environments for rapid testing applications include emergency ro

Grunenthal Group: Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks7.4.2021 11:39:12 CEST | Press release

• Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry • Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies like Pfizer and Roche (Aachen, Germany): Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector. “The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” said Gabriel Baertschi, CEO Grünenthal. “While we are proud to

DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life6.4.2021 09:15:56 CEST | Press release

The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible care solutions, to link to specialized advisors, doctors and digital solutions in obesity care, and by supporting them with the testimonials of peers who took action to better manage their health, all within one digital location. The program launches today in Germany with the intention to expand across other European markets.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom